Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Today, 10:40 AMAstraZeneca launches lung cancer drug Zegfrovy (sunvozertinib) in U.S. for EGFR exon 20-mutated NSCLC after FDA accelerated approval
Index
-
Market Cap
269.66B
Enterprise Value
297.00B
Income
10.45B
Sales
61.37B
Book/sh
32.43
Cash/sh
3.20
Employees
96100
IPO
Oct 17, 2003
P/E
25.99
Forward P/E
15.21
PEG
1.31
P/S
4.39
P/B
5.36
P/C
54.28
P/FCF
24.81
EV/EBITDA
14.78
EV/Sales
4.84
Quick Ratio
0.67
Current Ratio
0.89
Debt/Eq
0.64
LT Debt/Eq
0.52
Option/Short
Yes / Yes
EPS (ttm)
6.69
EPS next Y
11.43
EPS next Q
2.59
EPS this Y
11.93%
EPS next Y
11.49%
EPS next 5Y
11.59%
EPS past 3/5Y
45.90% 22.05%
Sales past 3/5Y
9.82% 16.31%
EPS Y/Y TTM
25.90%
Sales Y/Y TTM
8.61%
EPS Q/Q
2.26%
Sales Q/Q
6.41%
Insider Own
3.44%
Insider Trans
-0.02%
Inst Own
60.71%
Inst Trans
-1.05%
ROA
9.15%
ROE
21.99%
ROIC
13.69%
Gross Margin
73.93%
Oper. Margin
22.38%
Profit Margin
17.02%
SMA20
7.01%
SMA50
6.78%
SMA200
-3.67%
Trades
Shs Outstand
1.55B
Shs Float
1.50B
52W High
212.71 -18.26%
52W Low
153.41 13.33%
Volatility
1.53% 1.90%
ATR (14)
3.77
RSI (14)
66.13
Beta
0.33
Rel Volume
0.69
Avg Volume
3.38M
Volume
1,789,283
Perf Week
4.31%
Perf Month
6.45%
Perf Quarter
2.72%
Perf Half Y
-9.58%
Perf YTD
-0.93%
Perf Year
3.32%
Perf 3Y
35.98%
Perf 5Y
40.47%
Perf 10Y
191.24%
Prev Close
168.45
Price
173.87
Change %
3.22%
Date Action Analyst Rating Change Price Target Change
Sep-15-26Upgrade Deutsche Bank Sell → Hold
Sep-09-26Initiated RBC Capital Mkts Outperform
Jul-13-26Downgrade HSBC Securities Buy → Hold
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sharma ManiSee RemarksAug 08 '26Buy160.57203,24919,288Sep 11 04:05 PM
Sharma ManiSee RemarksMay 20 '26Sale185.7811,8932,209,48219,262May 22 04:05 PM
AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.
M.B.A.Mr. Pascal Claude Roland Soriot D.V.M.
CFO & Executive DirectorDr. Aradhana Sarin M.D.
EVP of Global opt. & ITMs. Pam P. Cheng
Head of Investor RelationsMr. Joris Silon
CHROMr. Jeffrey Pott J.D.